Import from "@/components/mdx"

Veozah and Finasteride Interaction: What Women Need to Know

Why a Woman Might Take Both Drugs at Once

Women taking fezolinetant for hot flashes and finasteride for hair thinning are a specific, underserved clinical population. Fezolinetant targets the neurokinin 3 (NK3) receptor in the hypothalamic thermoregulatory center to reduce vasomotor symptoms without estrogen. Finasteride, a 5-alpha reductase inhibitor, blocks the conversion of testosterone to dihydrotestosterone (DHT), which drives hair follicle miniaturization in female pattern hair loss (FPHL) and contributes to acne and hirsutism in PCOS.

The overlap matters because both conditions frequently occur together. PCOS affects approximately 8-13% of reproductive-age women, and the hyperandrogenism that defines it does not simply disappear at menopause. Perimenopausal women with a history of PCOS may still need androgen-targeted therapy even as they start managing hot flashes. Understanding whether these two drugs interact, and how, is not a footnote question. It is a real clinical scenario.

How Fezolinetant Works

Fezolinetant selectively antagonizes the NK3 receptor on KNDy neurons (kisspeptin, neurokinin B, dynorphin) in the arcuate nucleus. Neurokinin B signaling drives the vasomotor flush response, and blocking it reduces hot flash frequency and severity. The drug does not bind estrogen, progesterone, or androgen receptors. That is its primary appeal: non-hormonal relief.

How Finasteride Works in Women

Finasteride inhibits type II 5-alpha reductase, the enzyme that converts testosterone to DHT in hair follicles, skin, and liver. In women with FPHL or PCOS-related hyperandrogenism, lowering DHT levels can slow or partially reverse follicle miniaturization. Doses used in women typically range from 1 mg to 5 mg daily, though no dose is FDA-approved for any female indication. Use in women is entirely off-label.

The Pharmacokinetic Picture: Do These Drugs Interact at the Enzyme Level?

The short answer is: not in a clinically dangerous CYP-mediated way. But the details matter.

Fezolinetant's Metabolic Pathway

Fezolinetant is metabolized primarily by CYP1A2, with minor contributions from CYP2C9 and CYP2C19. The FDA label carries a strong warning: do not use fezolinetant with moderate or strong CYP1A2 inhibitors (such as fluvoxamine or ciprofloxacin) because plasma concentrations of fezolinetant can rise sharply, increasing hepatotoxicity risk. Strong CYP1A2 inducers (such as smoking or rifampicin) can reduce fezolinetant exposure and blunt its efficacy.

Finasteride's Metabolic Pathway

Finasteride is metabolized by CYP3A4. It does not inhibit or induce CYP1A2 at clinically relevant concentrations. This means finasteride is not expected to raise or lower fezolinetant blood levels through enzyme competition. That is reassuring, but it does not make the combination risk-free.

What the DDI Databases Show

Standard drug-drug interaction (DDI) checkers, including those from Lexicomp and Drugs.com, do not list a direct pharmacokinetic interaction between fezolinetant and finasteride. There is no shared transporter (P-glycoprotein or BCRP) interaction of known clinical significance between the two. The interaction risk that does exist is pharmacodynamic, not pharmacokinetic, and it sits at the level of androgen physiology and shared organ toxicity, specifically the liver.

The Pharmacodynamic Overlap: Androgen Pathway Considerations

Neither drug binds the androgen receptor directly. Fezolinetant does not alter circulating testosterone or DHT levels. Finasteride lowers DHT without changing total testosterone substantially in most women. So there is no direct additive or antagonistic receptor-level effect when you combine them.

The more nuanced concern is this: in perimenopausal women with PCOS or hyperandrogenism, the hormonal environment is already in flux. Estrogen is declining, which relatively amplifies androgen signaling even without any change in testosterone production. Adding finasteride to reduce DHT effects on the scalp and skin makes clinical sense in this context. Adding fezolinetant to address the hot flashes that emerge as estrogen drops also makes sense. But the two drugs are being layered onto an already-complex hormonal state, and neither has been studied in combination in women with PCOS or perimenopausal hyperandrogenism. That evidence gap is real and should be named clearly.

PCOS Across the Menopausal Transition

Women with PCOS entering perimenopause are a distinct group. The PCOS phenotype persists beyond reproductive years, with ongoing metabolic dysfunction, androgen excess, and irregular cycles often continuing into the late 40s and early 50s. Hot flashes in this population may begin earlier and be more severe than in women without PCOS. If you are in this group, your clinician needs to map out which symptom you are treating with which drug, and what the exit strategy looks like for each.

Liver Safety: The Shared Risk That Demands Monitoring

This is the interaction that deserves the most clinical attention.

Fezolinetant carries an FDA-labeled hepatotoxicity warning. In the SKYLIGHT 4 safety trial (52-week, double-blind, placebo-controlled), liver enzyme elevations meeting Hy's Law criteria were observed in the fezolinetant arm. The FDA requires liver function testing at baseline and at months 3 and 6 of treatment. Fezolinetant should be discontinued if ALT or AST exceeds five times the upper limit of normal.

Finasteride is also associated with hepatic enzyme elevations, though the signal is less well characterized in women given the limited female-specific trial data. Case reports of finasteride-associated hepatotoxicity in women exist in the literature, and standard prescribing caution includes baseline liver function assessment.

Combining two drugs with independent hepatic signals does not create a known synergistic liver toxicity, but it does mean your clinician should:

• Obtain a comprehensive metabolic panel before starting either drug
• Recheck liver enzymes at 3 months and 6 months, regardless of which drug was added first
• Hold a low threshold for discontinuing one drug if transaminases rise, to determine which agent is responsible

SKYLIGHT Trial Program: What the Data Actually Show

The SKYLIGHT program comprised four trials. SKYLIGHT 1 and 2 were the key 12-week efficacy trials showing that fezolinetant 45 mg once daily reduced moderate-to-severe hot flash frequency by approximately 60% versus placebo. SKYLIGHT 4 was the 52-week safety extension that generated the liver signal. Women in these trials were postmenopausal, with mean ages around 54 years. None of these trials enrolled women concurrently taking finasteride, so no direct combination data exist.

Pregnancy and Lactation: Both Drugs Are Contraindicated

This section is mandatory and the information here is not negotiable.

Finasteride: Category X Teratogen

Finasteride is FDA Pregnancy Category X. It causes feminization of male fetuses by blocking DHT synthesis during critical periods of urogenital development. Women of childbearing potential taking finasteride must use highly effective contraception throughout treatment and for at least one month after the last dose. Even skin contact with crushed or broken finasteride tablets is contraindicated during pregnancy.

If you are trying to conceive, finasteride must be stopped. Full stop.

Fezolinetant in Pregnancy

Fezolinetant is not approved for use during pregnancy. Animal studies show adverse embryofetal effects at doses relevant to human exposure. There are no adequate human pregnancy data. The FDA label states that fezolinetant should be discontinued if pregnancy is confirmed.

Because fezolinetant is indicated for menopausal vasomotor symptoms, most women taking it are postmenopausal or late perimenopausal. Pregnancy is unlikely but not impossible in the early perimenopause period. If you are perimenopausal and not certain you are past your fertile years, effective contraception remains relevant.

Lactation

Neither drug has adequate lactation safety data. Finasteride transfer into human breast milk has not been studied. Fezolinetant's transfer into breast milk is unknown. Because of the theoretical risks, both drugs should be avoided during breastfeeding.

Contraception Requirements When Taking Both

If you are of any reproductive potential and are taking finasteride:

1. Use a highly reliable contraceptive method (IUD, hormonal implant, tubal ligation, or consistent combined hormonal contraception).
2. Do not rely on barrier methods alone.
3. Confirm negative pregnancy status before starting or continuing finasteride.
4. Continue contraception for at least four weeks after stopping finasteride.

Fezolinetant does not have a contraceptive requirement built into its label the same way, but the advice above covers both drugs.

Who This Combination Is and Is Not Right For

Women for Whom This May Be Appropriate

• Postmenopausal women with confirmed ovarian failure who have both moderate-to-severe hot flashes and female pattern hair loss, and who have failed or declined hormone therapy for both indications.
• Perimenopausal women with PCOS and documented hyperandrogenism who need non-hormonal vasomotor symptom management and have an established clinical reason for finasteride.
• Women who cannot use estrogen-based hormone therapy (history of estrogen-sensitive malignancy, for example) and who also have significant androgen-driven hair loss.

In all these cases, the combination is being used for genuinely distinct indications. The prescribing logic holds. The monitoring plan must be explicit.

Women for Whom This Combination Is Not Appropriate

• Women who are pregnant, trying to conceive, or not using reliable contraception. Finasteride alone is disqualifying here.
• Women with pre-existing hepatic impairment. Fezolinetant is contraindicated in patients with severe hepatic impairment, and caution applies even in moderate impairment. Adding finasteride to an already-stressed liver increases unpredictability.
• Women taking moderate or strong CYP1A2 inhibitors (such as fluvoxamine, ciprofloxacin, or oral contraceptives that significantly inhibit CYP1A2) alongside fezolinetant, because that interaction is the real pharmacokinetic danger for fezolinetant, not finasteride.
• Women whose hair loss has not been evaluated for non-androgen causes. Thyroid dysfunction, iron deficiency, and alopecia areata are common in perimenopausal women and will not respond to finasteride.

Sex-Specific Pharmacology: What the Trials Did Not Fully Address

Women have been historically under-represented in pharmacokinetic and DDI trials for both of these drugs.

The SKYLIGHT trials enrolled exclusively women, which is a genuine strength for fezolinetant's efficacy and safety data. But the trials excluded women with significant comorbidities and did not assess combination therapy with finasteride or other androgen-pathway drugs. So the liver safety data from SKYLIGHT 4 applies to women as a group, not to women on concurrent androgen-targeted therapy.

Finasteride's clinical trial history is the opposite problem: most early finasteride pharmacokinetic studies were conducted in men. The doses used in women (1-5 mg) are extrapolated partly from male prostate data and partly from smaller female-specific trials in FPHL and PCOS. Women generally have lower circulating DHT levels than men, which may alter the dose-response curve. The evidence for 5 mg versus 1 mg in women is not settled.

The Menopause Society's 2023 position statement endorses fezolinetant as an effective non-hormonal option for vasomotor symptoms but does not address combination use with finasteride, because the combination has not been studied as a paired intervention.

Practical Counseling: What to Tell Your Clinician

If you are considering or already taking both drugs, bring this checklist to your next appointment:

• Ask for a baseline comprehensive metabolic panel with full liver function tests before starting either drug, or immediately if you are already on both.
• Ask specifically: "Have my liver enzymes been checked in the last three months?"
• Confirm your contraceptive status. If there is any chance you could conceive, finasteride is not safe.
• Ask whether your hair loss has been evaluated with a ferritin level, TSH, and a dermatologic assessment. Finasteride only helps androgen-driven loss.
• If you develop nausea, right-upper-quadrant discomfort, jaundice, or darkened urine on either drug, stop both and get same-day lab work.
• Review your full medication list for CYP1A2 inhibitors. Fluvoxamine, ciprofloxacin, certain oral contraceptives, and even high-dose caffeine (a CYP1A2 substrate competitive inhibitor at very high intake) can raise fezolinetant levels.

Drug Interaction Summary Table

| Parameter | Fezolinetant (Veozah) | Finasteride | Combined Concern | |---|---|---|---| | Primary metabolism | CYP1A2 | CYP3A4 | No shared CYP pathway | | Interaction with each other via CYP | None known | None known | No PK interaction expected | | Androgen receptor binding | None | None (enzyme inhibitor) | No direct PD overlap | | Hepatotoxicity signal | Yes, labeled warning | Yes, case reports | Additive liver monitoring needed | | Pregnancy safety | Contraindicated | Category X teratogen | Both must be avoided in pregnancy | | Lactation safety | Unknown | Unknown | Both should be avoided | | Female-specific trial data | Strong (SKYLIGHT 1, 2, 4) | Limited, mostly extrapolated | Evidence gap in combination | | DDI database classification | No interaction listed | No interaction listed | Pharmacodynamic caution applies |

Frequently Asked Questions